EGFR and non-small cell lung carcinoma: We speculated about a superior efficacy of DTX/RAM treatment in EGFR-positive than in EGFR-negative NSCLC patients, and the reported poor response of squamous cell carcinoma to DTX/RAM treatment may explain the improved survival in the ICI-untreated patients [21,22,23].